CDH1 and breast carcinoma: The overall analysis revealed that E-cadherin-negative breast cancer patients had a higher risk of mortality (pooled HR 1.79, 95% CI 1.41–2.27, Figure 2) with heterogeneity (I2 = 67.3%, P < 0.001).